Abstracts Archive - Page 304 of 2425 - ACR Meeting Abstracts

Abstract Number: 1912 • ACR Convergence 2023
Impact of Pharmacist-Led Specialty Medication Management Service on Time-to-Dispense for Specialty Rheumatologic Medications in a University Health System
Khashayar Ahmadmehrabi¹, Navin Ravishankar², Diana Mekhiel³ and Zineb Aouhab³, ¹Loyola University Medical Center, Oak Park, IL, ²Indiana University Health, Indianapolis, IN, ³Loyola University Medical Center, Maywood, IL
Background/Purpose: Given the progressive joint damage and physical disability associated with uncontrolled Rheumatoid arthritis (RA), a treat-to target-strategy through the early utilization of disease-modifying antirheumatic…
Abstract Number: 1923 • ACR Convergence 2023
Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre
Smruti Ramteke¹, sanjay Ramteke² and Sandeep Yadav³, ¹Arthritis Clinic, Jasleen Hospital, Nagpur, India, ²Government Super Speciality Hospital Nagpur, Nagpur, India, ³P D Hinduja national Hospital and medical Research centre, Mumbai, India
Background/Purpose: The prevalence of comorbidities in rheumatic diseases may vary by disease and geographic region. This study aimed to investigate the comorbidities associated with rheumatoid…
Abstract Number: 1410 • ACR Convergence 2023
The Use of the ASAS Referral Criteria Together with Increased Education and Training of Its Use Improves Delay to Diagnosis of Axial Spondyloarthritis
Antoni Chan, Kathryn Rigler and Arran McDougall, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom
Background/Purpose: Early diagnosis of axial spondyloarthritis (AxSpA) remains a challenge in the management of this condition worldwide. Over the last decade, there remains a significant…
Abstract Number: 0416 • ACR Convergence 2023
Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study
Rakesh Kumar¹, Edward Lovering¹, Chanakya Kodishala², Sara Achenbach³, Diego Carvalho¹, Cynthia Crowson¹, John Davis¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester Minnesota, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Some sleep disorders (SD) are more prevalent in patients with chronic inflammatory diseases, such as Rheumatoid Arthritis (RA). However, most of the research has…
Abstract Number: 0422 • ACR Convergence 2023
Electronic Health Record-Based Machine Learning Model for Predicting Disease Activity in Patients with Rheumatoid Arthritis
Zelin Yun¹, Chun Li² and Zhanguo Li², ¹Peking University People's Hospital, Beijing, China, ²Peking University People’s Hospital, Beijing, China
Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent chronic inflammatory diseases in which synovitis gradually leads to polyarthritis and joint destruction. Poor response…
Abstract Number: 0427 • ACR Convergence 2023
Molecular Characterization of Biologic and Targeted Synthetic DMARDs Effects Through Ex- vivo Studies in Rheumatoid Arthritis Immune Cells
Laura Muñoz-Barrera¹, Carlos Perez-Sanchez², Laura Romero-Zurita¹, Rafaela Ortega Castro³, Jerusalem Calvo⁴, Pilar Font Ugalde¹, Marta Rojas⁵, Ismael Sanchez-Pareja¹, Maria del Carmen Abalos-Aguilera⁶, Desiree Ruiz-Vilchez¹, Christian Merlo-Ruiz¹, Mª Angeles Aguirre⁷, Nuria Barbarroja⁸, Tomás Cerdó¹, Eduardo Collantes Estévez⁹, Marta Alarcon-Riquelme¹⁰, Alejandro Escudero Contreras⁴ and Chary Lopez-Pedrera¹¹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²IMIBIC, Córdoba, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain, ⁵Hospital Universitario Reina Sofía, Cordoba, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁷Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁸University of Cordoba, Córdoba, Spain, ⁹Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ¹⁰Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, a significant proportion of patients (10-30%) fail to respond to current medications, including biologics. A better characterization…
Abstract Number: 0430 • ACR Convergence 2023
A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis
Maria Lopez-Lasanta¹, Helena Borrell¹, Meritxell Salles Lizarzaburu², Virginia Ruiz-Esquide³, Daniel Roig⁴, Annika Nack⁵, Carolina Pérez⁶, Julia Bernardez⁷, Andrea García⁸, Joana Rovira⁹, Andrea Cuervo¹⁰, Marta Valls¹¹, Carmen Garcia¹², Sonia Minguez¹³, Rosa Morla¹⁴, Paula Estrada⁴, Melania Martinez¹⁵, Conxita Pitarch¹⁶, Noemi Busquets¹⁷, Hye Park¹⁸, Jose A Gomez-Puerta¹⁹, Susana Holgado²⁰, Nuria Montala²¹, Raimon Sanmarti³, Lourdes Mateo²⁰, Cesar Diaz²², Hector Corominas²³ and Georgina Salvador⁷, ¹Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²C. H. de Manresa - Fundació Althaia, Barcelona, Spain, ³Hospital Clinic, Rheumatology, Barcelona, Spain, ⁴Hospital Moisses Broggi, Rheumatology, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital del Mar-Parc de Salut Mar, Rheumatology, Barcelona, Spain, ⁷Hospital Mutua Terrassa, Rheumatology, Barcelona, Spain, ⁸Hospital Sant Pau-Dos de Maig, Rheumatology, Barcelona, Spain, ⁹Hospital de Mollet, Barcelona, Spain, ¹⁰Hospital Granollers, Rheumatology, Barcelona, Spain, ¹¹Hospital Josep Trueta, Rheumatology, Girona, Spain, ¹²Hospital de Terrassa, Rheumatology, Barcelona, Spain, ¹³Fundació Althaia, Manresa, Spain, ¹⁴Hospital Clinic, Rheumatology, Barcelona, Barcelona, Spain, ¹⁵Hospital Germans Trias i Pujol, Rheumatology, Barcelona, Spain, ¹⁶Hospital Universitari de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Spain, ¹⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ¹⁸Hospital Universitari Sant Pau, Rheumatology, Barcelona, Spain, ¹⁹Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ²⁰Hospital Universitari Germans Trias i Pujol, Rheumatology, Barcelona, Spain, ²¹Hospital Santa Maria, Rheumatology, Lleida, Spain, ²²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²³Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain
Background/Purpose: The Janus Kinase inhibitors (JAKi) drugs are approved for use in adults with moderate to severe rheumatoid arthritis (RA). Real-world studies are necessary as…
Abstract Number: 0440 • ACR Convergence 2023
Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Ting Wang¹, Natalia V. Giltiay², Christian Lood² and Bobby Kwanghoon Han², ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). However, data on predictive biomarkers associated with therapeutic response…
Abstract Number: 0425 • ACR Convergence 2023
Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Ioasaf Karafotias, Joshua Rothwell, Maryam Adas, Bechman Katie, Mark Russell, Sam Norton and James Galloway, King's College London, London, United Kingdom
Background/Purpose: Rituximab targets CD20-bearing B cells and is used to treat Rheumatoid Arthritis (RA). Common Variable Immune Deficiency (CVID) is a primary immune deficiency syndrome…
Abstract Number: 0452 • ACR Convergence 2023
Real Life Safety and Survival of Targeted Therapies in Arthritis Patients over Age of 65
Elena Grau Garcia¹, Pablo Francisco Muñoz Martínez², Laura Mas Sanchez³, Alba Maria Torrat Noves¹, Daniel Ramos Castro¹, Carmen Riesco Barcena¹, Anderson Victor Huaylla Quispe¹, Iago Alcantara Alvarez¹, Belen Villanueva Mañez¹, Samuel Leal Rodriguez¹, Ines Canovas Olmos¹, Hikmat Charia¹, Marta De la Rubia Navarro¹, Luis Gonzalez Puig¹, Jose Ivorra Cortes¹, Isabel Martinez Cordellat¹, Carmen Najera Herranz¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Ernesto Tovar Sugrañes¹, Elvira Vicens Bernabeu¹ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Sagunto, Spain, ³Rheumatology Department. HUP La Fe, Valéncia, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Prognosis for chronic inflammatory arthritis is drastically improved over previous decades and older patients are treated with targeted therapies (TTs) (biological or synthetic targeted…
Abstract Number: 0426 • ACR Convergence 2023
The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis
Tomokazu Choshi¹, Kenji Mamoto¹, Yutaro Yamada¹, Tadashi Okano¹, Shohei Anno², Kazuki Orita², Takahiro Iida³, Masahiro Tada⁴, Kentaro Inui⁵, Tatsuya Koike⁶ and Hiroaki Nakamura¹, ¹Osaka Metropolitan University, Osaka, Japan, ²Yodogawa Christian Hospital, Osaka, Japan, ³Koryokai Hospital, Osaka, Japan, ⁴Osaka City General Hospital, Osaka, Japan, ⁵Saiseikai Nakatsu Hospital, Osaka, Japan, ⁶Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: Some patients with rheumatoid arthritis (RA) need switching therapy between biologic agents (Bio) and Janus kinase inhibitors (JAKi) when efficacy of Bio or JAKi…
Abstract Number: 0441 • ACR Convergence 2023
Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Dimitrios Pappas¹, Jacqueline O’Brien¹, Lin Guo¹, Ying Shan¹, Joshua Baker², Gregory Kricorian³, Scott Stryker⁴ and David Collier³, ¹CorEvitas, LLC, Waltham, MA, ²University of Pennsylvania, Philadelphia, PA, ³Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA
Background/Purpose: Ongoing debate exists regarding the optimal sequence of tumor necrosis factor inhibitors and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) as…
Abstract Number: 0450 • ACR Convergence 2023
Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting
Martinus Van de Laar¹, Martijn Oude Voshaar¹, Peter ten Klooster¹, Danyta Tedjo² and celine van de laar³, ¹University of Twente, Hengelo (OV), Netherlands, ²TiH @ University of Twente, Hengelo (OV), Netherlands, ³Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands
Background/Purpose: The EULAR guidelines for Rheumatoid Arthritis (RA) patients advise to use a strategy aiming at a predefined target of disease activity (T2T). If this…
Abstract Number: 0447 • ACR Convergence 2023
Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER
Lucia Otero-Valera¹, Jose María Alvaro-Gracias², Jerusalem Calvo³, Cristina Campos⁴, Alicia Garcia Dorta⁵, Fernando Sánchez-Alonso⁶ and Isabel Castrejon⁷, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³Reina Sofia University Hospital, Córdoba, Spain, ⁴Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Fundación Española de Reumatología, Madrid, Spain, ⁷Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Glucocorticoids are frequently used as bridging therapy for rheumatoid arthritis (RA) patients starting conventional synthetic DMARDs. Both EULAR and ACR guidelines (1,2), recommend to…
Abstract Number: 0458 • ACR Convergence 2023
Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience
Maria Rodriguez Laguna¹, Zulema Rosales-Rosado², Cristina Vadillo-Font¹, Jose Pierre Otazu-Moudelle¹, Inés Pérez Sancristóbal¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone an enormous change in the last two decades with the use of biological Disease Modifying Drugs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].